Primary Biliary Cholangitis clinical trials at UCSF
1 research study open to eligible people
Showing trials for
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
open to eligible people ages 18-75
To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo
San Francisco, California and other locations
Last updated: